The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?
<p>Abstract</p> <p>There is a plethora of published cancer biomarkers but the reality is that very few, if any, new circulating cancer biomarkers have entered the clinic in the last 30 years. I here try to explain this apparent oxymoron by classifying circulating cancer biomarkers...
Main Author: | Diamandis Eleftherios P |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-08-01
|
Series: | BMC Medicine |
Subjects: | |
Online Access: | http://www.biomedcentral.com/1741-7015/10/87 |
Similar Items
-
A List of Candidate Cancer Biomarkers for Targeted Proteomics
by: Malu Polanski, et al.
Published: (2006-01-01) -
What is a biomarker?: From its discovery to clinical application
by: Majkić-Singh Nada
Published: (2011-01-01) -
Biomarker discovery for ALS by using affinity proteomica
by: Mohsenchian, Atefeh
Published: (2012) -
Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development
by: Maria Frantzi, et al.
Published: (2014-12-01) -
Fast quantitative urinary proteomic profiling workflow for biomarker discovery in kidney cancer
by: Lin Lin, et al.
Published: (2018-12-01)